Invitation to presentation of Spago Nanomedical AB’s year-end report for 2016
Spago Nanomedical AB publishes its year-end report for 2016 on February 14.
For this reason the company invites investors, analysts, and media to a presentation on Tuesday, February 14 at 9:30 CET, at Nyhetsbyrån Direkt, Jakobsbergsgatan 13 in Stockholm. CEO Mats Hansen presents on the company development and respond to questions. Send notification of participation to firstname.lastname@example.org.
The presentation will also be broadcasted in real time online and can be viewed via Spago Nanomedical´s home page www.spagonanomedical.se where it also will be available afterwards.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, email@example.com.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.
The aim of SpagoPix is to improve cancer diagnostics using magnetic resonance imaging (MRI) by facilitating early discovery of tumors and metastases. Early discovery improves the chances of efficient treatment and survival of cancer patients. Tumorad® is a further development of the company´s proprietary nanoparticles with the purpose of delivering radionuclides for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer.
For further information, see www.spagonanomedical.se.